Haemonetics 4th Quarter Fiscal 2022 Earnings Release Available on Investor Relations Website

Financial press release available online

BOSTON, May 10, 2022 /PRNewswire/ — Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter of fiscal 2022, which ended April 2, 2022are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results to 8:00 a.m. EDT on May 10, 2022. The conference call and webcast can be accessed with the following information:

  • WE / Canada toll free (877) 848-8880; International (716) 335-9512

  • Conference ID required for access: 5347317

  • A live webcast of the call can be accessed on the Haemonetics Investor Relations website or via the following link: https://edge.media-server.com/mmc/p/gooqch6s

In addition, the Company has posted on its Investor Relations website the earnings release and analytical tables and additional information that will be referenced during its conference call and webcast, the direct links of which are available below. below.

Direct link to 4Publication of Q FY22 results:

Direct link to 4Q FY22 analytical tables and additional information:

A replay of the conference call and webcast will be available for one year from May 10, 2022to 11:00 a.m. EDT using the conference call webcast link provided in this press release.

About hemonetics
Hemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions to its customers, to help them improve patient care and reduce the cost of healthcare. Our technology is aimed at important medical markets: the collection of blood and plasma components, the operating room and hospital transfusion services. To learn more about Hemoneticsto visit www.haemonetics.com.



Show original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-4th-quarter-fiscal-year-2022-earnings-release-available-on-investor-relations-website-301543450.html

SOURCEHaemonetics Corporation

Comments are closed.